mir210 and BCL2 Expressions in Patients with Acute Myeloid Leukemia

Objective: Acute myeloid leukemia (AML) is a heterogeneous, malignant disease, characterized by disruption of differentiation of hematopoietic stem cells. The effect of microRNAs (miRNA)-210 on the prognosis of AML is a subject of research. BCL-2 is a protooncogene encoding a protein that inhibits apoptosis. Overexpression of BCL-2 is seen in AML cells. The presence or absence of cytogenetic abnormalities is an important prognostic marker in AML. In our study, we aimed to compare the effect of miRNA-210 and BCL-2 expressions on the prognosis of AML and the relationship with the cytogenetic findings. Methods: Cytogenetic analyzes were performed in bone marrow and/or peripheral blood samples taken from patients with AML and healthy individuals. miR-210 and BCL-2 mRNA levels were determined by quantitative real-time polymerase chain reaction method. Results: No abnormality was found in healthy individuals. Clonal structural and numerical anomalies were detected in some patients with AML. BCL-2 mRNA expression levels of leukocytes and bone marrow samples of patients with AML were higher than that of the leukocytes of healthy individuals. miR-210 levels did not differ between patients and healthy individuals. The miR-210 level of leukocytes of patients with AML was significantly higher than that of the bone marrow samples of the patients with AML. A positive correlation was found between BCL-2 and miR-210 in bone marrow samples from patients with AML. Conclusion: The increase in BCL-2 mRNA and miR-210 levels may have negative effects on the prognosis of the disease by causing disruption in the apoptosis mechanisms.